CarolePaleyMD

PubMed

• 7 citations
  JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy
  Alessandro M. Vannucchi, Andrea Mortara, Andrea D’Alessio, Mara Morelli, Alberto Tedeschi
  Journal of Clinical Medicine. 2021-08-23
• 9 citations
  Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk...
  Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey
  Hematological Oncology. 2021-07-05
• 23 citations
  Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
  Vikas Gupta, Martin Griesshammer, Bruno Martino, Lynda Foltz, Renato Tavares
  Leukemia & Lymphoma. 2021-03-21

Journal Articles

• The Palatability and Tolerability of Deferasirox Taken with Different Beverages or Foods  
  Goldberg SL, Giardina PJ, Chirnomas D. Esposito J, Paley C, Vichinsky E, Pediatric Blood Cancer, 9/1/2013
• Phase II Trial of Panobinostat, an Oral Pan-Deacetylase Inhibitor in Patients with Primary Myelofibrosis, Post-Essential Thrombocythaemia, and Post-Polycythaemia Vera ...  
  Deangelo D, Mesa R, Fiskus W, Tefferi A. Paley C, Wadleigh M, Ritchie E, Snyder D, Degna K. Ganguly S, Ondovik M, Rine J, Bhalla K, Br J. Haematol, 5/23/2013
• Age-Related Treatment Patterns in Sickle Cell Disease Patients and the Associated Sickle Cell Complications and Healthcare Costs  
  Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Duh M, Pediatric Blood Cancer, 5/1/2013
• PANORAMA 2: Panobinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Myeloma  
  Richardson P, Schlossman R, Alsina M, Weber D, Coutre S, Gasparetto G, Mukhopadhyay S, Ondovik M, Khan M, Paley C, Lonial S, Blood, 1/1/2013
• Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients with Myelodysplastic Syndrome  
  List A, Baer M, Steensma D, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E, Journal of Clinical Oncology, 6/1/2012
• Relationship Between LPI, LIC and Cardiac Response in a Deferasirox Monotherapy Trial  
  Wood J. Glynos T, Thompson A, Giardina P, Harmatz P, Kang B, Paley C, Coates T, Haematologica, 7/1/2011
• Prospective Assessment of Effects of Iron Overload Parameters of Deferasirox Therapy in Patients with Myelodysplastic Syndromes  
  Greenberg P, Koller C, Cabantchik Z, Warsi G, Glynos T, Paley C, Schiffer C, Leukemia Research, 12/1/2010
• Follow up Report on the 2-year Cardiac Data from a Deferasirox Monotherapy Trial  
  Wood J, Glynos T, Thompson A, Giardina P, Harmatz P, Kang, B, Paley C, Coates T, Am J Hematol, 10/1/2010
• The Effect of Deferasirox on Cardiac Iron in Thalassemia Major: Impact of Total Body Iron Stores  
  Wood J, Kang B, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates T, Blood, 7/29/2010
• Treatment of Transfusional Iron Overload in Patients with Myelodysplastic Syndrome or Severe Anemia: Data from Multicenter Clinical Practices  
  Raptis A, Duh M, Wang S, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J, Transfusion, 1/1/2010
• Serum Ferritin Level Changes in Children with Sickle Cell Disease on Chronic Blood Transfusion are Nonlinear and are Associated with Iron Overload and Liver Injury  
  Adamkiewicz T, Abboud M, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E, Casella J, Alvarez O, Barredo J, Lee M, Iyer R, Kutlar A, McKie K, Odo N, Gee B, Kwiatkowski ..., Blood, 11/19/2009
• Deferasirox Pharmacokinetics in Patients with Adequate Versus Inadequate Response  
  Chirnomas D, Smith AL, Braunstein J, Finkelstein Y, Pereira L, Bergmann A, Grant F, Paley C, Shannon M, Neufeld E, Blood, 11/5/2009
• Adherence to Deferasirox in Children and Adolescents with Sickle Cell Disease During 1 Year of Therapy  
  Alvarez O, Rodriguez-Cortes H, Robinson N, Lewis N, Pow Sang C, Lopez-Mitnik G, Paley C, Journal of Pediatric Hematology/Oncology, 10/31/2009
• Diagnosing and Treating Diamond Blackfan Anemia: Results of An International Consensus Conference  
  Vlachos A, Ball S, Dahl N, Alter B, Sheth S, Ramenghi U, Meerpohl J, Karlsson S, Liu J, Leblanc T, Paley C, Kang E, Leder E, Atsidaftos E, Shimamura A, Bessler M, Glad..., Br J Hematol, 9/1/2008
• Recurrent Attacks of Facial Nerve Palsy as the Presenting Sign of Leukemic Relapse  
  Dukhee R, Myssiorek D, Zahtz G, Diamond A, Paley C, and Shende A, Laryngoscope, 2/1/2002
• Clinical Significance of RBC Alloantibodies and Autoantibodies in Sickle Cell Patients Who Received Transfusions  
  Aygun B, Padmanabban S, Paley C, and Chandrasekaran V, Transfusion, 1/1/2002
• Thrombocytopenia Absent Corpus Callosum Syndrome: A Third Case of a Distinct Clinical Entity  
  Khabbaze Y, Karayalcin G, Paley C, Shende A, and Lipton J, Journal of Pediatric Hematology/ Oncology, 10/1/2001
• A Denovo Lineage Switch from B-cell Acute Lymphoblastic Leukemia to Acute Myeloid Leukemia: A Case Report  
  Shende A, Zaslav A, Redner A, Bonagura V, Hatam L, Paley C, Lanzkowsky P, American Journal of Hematology, 1/1/1995
• Papillary Cystic Neoplasm of the Pancreas  
  Poustchi-Amin M, Leonidas J, Valderrama E, Shende, A, Paley C, and Lanzkowsky P, Pediatric Radiology, 1/1/1995
• Systemic Necrotizing Vasculitis Associated with Childhood Sarcoidosis: Report of a Case and Review of the Literature  
  Kwong T, Valderrama E, Paley C, and Ilowite N, Seminars in Arthritis and Rheumatism, 1/1/1994
• Erythrocyte Depleted Allogeneic Human Umbilical Cord Blood Transplantation  
  Pahwa R, Fleisher A, Shih S, Uckan D, Shende A, Redner A, Paley C, Blood Cells, 1/1/1994
• Join now to see all

Books/Book Chapters

• Pediatric Hematopoietic Stem Cell Transplantation 
  Chapter: Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia 
  Paley C, Vlachos A, Lipton JEditors: Ron Kline.Informa Healthcare2006
• Pediatric Hematopoietic Stem Cell Transplantation 
  Chapter: Hematopoietic Stem Cell Transplantation for the Inherited Bone Marrow Failure Syndromes 
  Vlachos A, Paley C, Lipton JEditors: Ron Kline.Informa Healthcare2006
• Manual of Pediatric Hematology and Oncology 
  Chapter: Thalassemia 
  Paley C, Lanzkowsky PEditors: Philip Lanzkowsky.Academic Press, NYEdition 3rd,1999
• Manual of Pediatric Hematology and Oncology 
  Chapter: Hematologic Manifestations of Systemic Illness 
  Paley C, Karayalcin G, and Lanzkowsky PEditors: Philip Lanzkowsky.Academic Press, NYEdition 3rd,1999
• Manual of Pediatric Hematology and Oncology 
  Chapter: Lymphadenopathy and Splenomegaly 
  Paley C, Lanzkowsky PEditors: Philip Lanzkowsky.Academic Press, NYEdition 3rd,1999
• Manual of Pediatric Hematology and Oncology 
  Chapter: Supportive Care and Management of Oncologic Emergencies 
  Paley C, Lanzkowsky PEditors: Philip Lanzkowsky.Academic Press, NYEdition 3rd,1999
• Manual of Pediatric Hematology and Oncology 
  Chapter: Retinoblastoma 
  Paley C, Lanzkowsky PEditors: Philip Lanzkowsky.Academic Press, NYEdition 3rd,1999
• Manual of Pediatric Hematology and Oncology 
  Chapter: Rhabdomyosarcoma 
  Paley C, Lanzkowsky PEditors: Philip Lanzkowsky.Academic Press, NYEdition 3rd,1999
• Manual of Pediatric Hematology and Oncology 
  Chapter: Rhabdomyosarcoma and Soft Tissue Sarcomas 
  Paley C, Lanzkowsky PEditors: Philip Lanzkowsky.Churchill LivingstoneEdition 2nd,1994
• Join now to see all

Abstracts/Posters

• PANORAMA 2: Panobinostat, Bortezomib, and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Myeloma - Poster Presentation
  Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gaspareto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley C, Lonial S, IMW, 1/1/2013
• Clinical Response by Baseline Characteristics in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma Treated with Panobinostat, Bortezomib, and Dexametha...
  Richardson P, Schlossman R, Alsina M, Coutre SE, Gasparetto C, Mukhopadhyay S. Ondovik M, Khan M, Paley C, Lonial S, ASCO, EHA, 1/1/2013
• Age-Related Emergency Department Reliance and Healthcare Resource Utilization in Patients with Sickle Cell Disease - Oral Presentation
  Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS, ASH, 1/1/2012
• Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D - Poster Presentation
  Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A, ASH, 1/1/2012
• Deferasirox is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes - Oral Presentation
  Zeidan A, Hendrick F, Friedman E, Gore S, Baer M, Sasane M, Paley C McNally D, Davidoff A, ASH, 1/1/2012
• 12-month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-year, Prospective, Noninterventional Registry Trial - Poster Presentation
  Heeney M, Mueller B, Baltz B, Adams-Graves P, Yang E, Paley C Esposito J, Vichinsky E, ASH, 1/1/2012
• Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis at 36 months - Poster Presentation
  Lyons R, Marek B, Paley C Esposito J, Garbo L, DiBella N, Garcia-Manero G, ASH, 1/1/2012
• PANORAMA 2: A Phase II Study of Panobinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma - ...
  Alsina M, Schlossman RL, Weber DM, Coutre SE, Lonial S, Gasparetto C, Warsi G, Ondovik M, Mukhopadhyay S, Paley C, Richardson PG, ASCO, EHA, 1/1/2012
• Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications - Oral Presentation
  Blinder M, Vekeman F, Trahey A, Sasane M, Paley C Duh M, Association of Pediatric Hematology/Oncology Nurses, 1/1/2012
• Age-Related Emergency Department Reliance (EDR) in Patients with Sickle Cell Disease (SCD) Complications - Poster Presentation
  Blinder M, Vekeman F, Trahey A, Sasane, Duh M, Paley C, ASH, 1/1/2012
• Baseline Characteristics and Medical History of Patients with Sickle Cell Disease in an Ongoing 3-year, Prospective, Noninterventional Registry Trial - Oral Presentation
  Heeney, M, Mueller B, Baltz B, Paley C, Esposito J, Sharma S, Vichinsky E, Sickle Cell Disease Association of America, 1/1/2012
• Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD) - Poster Presentation
  Blinder M, Vekeman F, Trahey A, Sasane, Duh M, Paley C, ASPHO, 1/1/2012
• Iron-Chelating Therapy (ICT) Treatment Discontinuation, Hospitalization, and Costs in Medicaid Enrollees with Sickle Cell Disease (SCD) in the United States - Poster P...
  Sasane M, Armstrong E, Skrepnek G, Ballas S, Paley C, ASPHO, 1/1/2012
• PANORAMA 2: Panobinostat, combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma - Poster Presentation
  Richardson P, Alsina M, Weber DM, Coutre S, Lonial S, Gaspareto C, Mukhopadhyay S, Ondovik M, Khan M, Paley C, Schlossman R, ASH, 1/1/2012
• Age-Related Blood Transfusion Patterns in Patients with Sickle Cell Disease (SCD) and the Association with Sickle Cell Complications - Oral Presentation
  Blinder M, Vekeman F, Trahey A, Sasane M, Paley C, Duh M, ASH, 1/1/2011
• A Phase II Trial of Panobinostat, an Orally Available Deacetylase Inhibitor (DACi) in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET), a...
  DeAngelo D, Tefferi A, Fiskus W, Mesa R, Paley C, Wadleigh M, Snyder D, Begna K, Ondovik M, Rine J, Bhalla K, ASH, 1/1/2011
• The palatability and Tolerabilityof Deferasirox (Exjade) Taken with Meals, Different Liquids, or Crushed and Added to Food - Poster Presentation
  Giardina P, Goldberg S, Parkhurst Cain J, Chirnomas D, Esposito J, Paley C, Vichinsky E, ASPHO, 1/1/2011
• A 12-Month Follow-up of an Ongoing Prospective, Non-Interventional, Multicenter Registry in Iron Overloaded Patients with Lower-risk Myelodysplastic Syndromes - Poster...
  Garcia-Manero G, Marek B, Lyons R, Martinez-Lopez N, Esposito J, Paley C, DiBella N, International Symposium on Myelodysplastic Syndromes, 1/1/2011
• The Palatability and Tolerability of Deferasirox Taken with Different Liquids or Food - Poster Presentation
  Goldberg S, Giardina P, Cain J, Chirnomas D, Esposito J, Paley C, Vichinsky E, European Hematology Association, 1/1/2011
• Baseline Characteristics of Patients with Sickle Cell Disease in an Ongoing 5-year, Prospective, Noninterventional Registry Trial - Poster Presentation
  Heeney, M, Mueller B, Baltz B, Paley C, Esposito J, Sharma S, Vichinsky E, ASH, 1/1/2011
• 24 Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower Risk MDS Patients - Poster Presentation
  Lyons R, Marek B, Sharma S, Paley C, Esposito J, Garbo L, DiBella N, Garcia-Manero G, ASH, 1/1/2011
• Age-Related Iron Chelation Utilization and Healthcare Costs in Patients with Sickle Cell Disease (SCD) - Oral Presentation
  Blinder M, Vekeman F, Trahey A, Sasane M, Paley C, Duh M, ASH, 1/1/2011
• A Phase II Trial of Oral Panobinostat, (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET)...
  DeAngelo D, Tefferi A, Mesa R, Paley C, Wadleigh M, Snyder D, Ondovik M, Rine J, Bhalla K, ASCO, 1/1/2010
• An Assessment of the Long-Term Efficacy and Safety of Deferasirox (Exjade, ICL670), a Once-Daily Oral Iron Chelator, in Pediatric Patients - Poster Presentation
  Vichinsky E and Paley C, ASPHO, 1/1/2008
• Another Family with Autosomal Dominant Congenital Hypoplastic Anemia (CHA) - Poster Presentation
  Paley C, Levin M, Karayalcin G, ASPHO, 1/1/2007
• Join now to see all

Other

• Peer Reviewer for “Hematologic Guidelines for the Care of Children and Adolescents With HIV Infection” 
  Paley C, New York State Department of Health
  1/1/2001